135 related articles for article (PubMed ID: 22079472)
1. Transplantation for lymphoma: good for the brain as well as the body?
Bierman PJ; Armitage JO
Biol Blood Marrow Transplant; 2012 Jan; 18(1):1-2. PubMed ID: 22079472
[No Abstract] [Full Text] [Related]
2. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
3. Treatment of primary CNS lymphoma.
Schmitz N
Blood; 2015 Feb; 125(9):1360-1. PubMed ID: 25721041
[TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
5. Putting caution in TEAM: high-dose chemotherapy with autologous HSCT for primary central nervous system lymphoma.
Tombleson RL; Green MR; Fancher KM
Bone Marrow Transplant; 2012 Oct; 47(10):1383-4. PubMed ID: 22426753
[No Abstract] [Full Text] [Related]
6. Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: complications and outcome.
Kumar L; Ganessan P; Ghosh I; Panda D; Gogia A; Mandhania S
Natl Med J India; 2010; 23(6):330-5. PubMed ID: 21561042
[TBL] [Abstract][Full Text] [Related]
7. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
8. A Tale of Two Eras: The Story of Autologous Stem Cell Transplantation with and without Thiotepa for Primary Central Nervous System Lymphoma.
Hu B
Biol Blood Marrow Transplant; 2019 May; 25(5):e141-e142. PubMed ID: 30878604
[No Abstract] [Full Text] [Related]
9. Allogeneic transplantation for lymphoma: risk-benefit balance is in the eye of the beholder.
Smith MR
Biol Blood Marrow Transplant; 2014 Jul; 20(7):905-6. PubMed ID: 24831132
[No Abstract] [Full Text] [Related]
10. Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Philippe L; Helias P; Puyraveau M; Boulahdour H; Deconinck E; Daguindau E
Bone Marrow Transplant; 2016 Aug; 51(8):1140-2. PubMed ID: 27042844
[No Abstract] [Full Text] [Related]
11. Acute coronary syndrome upon receiving carmustine infusion before autologous stem-cell transplantation.
Waibel Pachinger C; Rosselet A; Berthouzoz S; Luthi F; Ketterer N
Hematol Oncol; 2012 Dec; 30(4):216-8. PubMed ID: 22287477
[No Abstract] [Full Text] [Related]
12. Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors.
Marachelian A; Butturini A; Finlay J
Bone Marrow Transplant; 2008 Jan; 41(2):167-72. PubMed ID: 18176620
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma.
Maeng CH; Ko YH; Lim DH; Kang ES; Choi JY; Kim WS; Kim SJ
Cancer Res Treat; 2017 Jan; 49(1):92-103. PubMed ID: 27188204
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Holmberg LA; Stewart FM
Oncology (Williston Park); 2003 May; 17(5):627-32, 635, 640; discussion 640-2. PubMed ID: 12800792
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions.
Ramsdale E; Van Besien K
Leuk Lymphoma; 2011 Aug; 52(8):1415-7. PubMed ID: 21599586
[No Abstract] [Full Text] [Related]
16. [High dose therapy and hematopoietic stem cell transplantation in non-Hodgkin's lymphomas].
Hansz J
Pol Arch Med Wewn; 2001; 105 Suppl():159-61. PubMed ID: 12412241
[No Abstract] [Full Text] [Related]
17. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
Kasamon YL; Jones RJ; Piantadosi S; Ambinder RF; Abrams RA; Borowitz MJ; Morrison C; Smith BD; Flinn IW
Biol Blood Marrow Transplant; 2005 Feb; 11(2):93-100. PubMed ID: 15682069
[TBL] [Abstract][Full Text] [Related]
18. FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Ashizawa M; Kako S; Wada H; Sakamoto K; Sato M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Kanda Y
Hematol Oncol; 2012 Mar; 30(1):50-2. PubMed ID: 21574175
[No Abstract] [Full Text] [Related]
19. Indications for early autologous stem cell transplantation in aggressive lymphoma.
Kluin-Nelemans HC
Ann Hematol; 2001; 80 Suppl 3():B121-2. PubMed ID: 11757692
[No Abstract] [Full Text] [Related]
20. Allogeneic stem cell transplantation for patients with resistant high-grade lymphoma: what is the potential of reduced-intensity conditioning?
Dreger P
Ann Oncol; 2002 Sep; 13(9):1507. PubMed ID: 12196382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
